On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives from Biolake participated, including Deputy Director of East Lake High-Tech Zone, Director of Biological Department, Changchun Dan and Biological department leaders Zhongyu Yan and Yunhua Yuan.
GE Healthcare Life Sciences is a business unit of GE Healthcare (NYSE: GE). GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.
JHL Biotech and GE Healthcare will build a monoclonal antibody manufacturing plant under current good manufacturing practices (cGMP). The base construction will use GE Healthcare’s latest KUBio module plant technology. KUBio is a new approach to readily establish biopharmaceutical manufacturing capacity by delivering customers a fully functional, ready-to-run bioprocessing facility in 14-18 months, which is significantly shorter than constructing a traditional facility.